References
- AdachiKHashimotoTHamamotoNSymptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazoleJ Gastroenterol Hepatol2003181392814675268
- AdachiKKatsubeTKawamuraACYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazoleAliment Pharmacol Ther20001412596611012469
- AndoTKatoHSugimotoNA comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differencesDig Dis Sci20055016253116133961
- ArchimandritisAJNikolopoulouVKouklakisGEffects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance studyCurr Med Res Opin2005216031015899110
- BarthJPerdomoCSloanSRabeprazole maintains GERD healing in patients with Barrett’s esophagusAm J Gastroenterol1999942579
- BellNJBurgetDHowdenCWAppropriate acid suppression for the management of gastro-oesophageal reflux diseaseDigestion199251Suppl 159671397746
- BesanconMSimonASachsGSites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagentsJ Biol Chem199727222438469278394
- BirbaraCBreiterJPerdomoCRabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study GroupEur J Gastroenterol Hepatol2000128899710958216
- BourBStaubJLChoustermanMLong-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatmentAliment Pharmacol Ther2005218051215801915
- Bruley Des VarannesSGharibHBichelerVEffect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjectsAliment Pharmacol Ther20042089990715479362
- BurgetDWChivertonSGHuntRHIs there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppressionGastroenterology199099345512142113
- BytzerPBlumADe HerdtDSix-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux diseaseAliment Pharmacol Ther200420181815233698
- CaosABreiterJPerdomoCLong-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United StatesAliment Pharmacol Ther20052219320216091056
- CaosAMoskovitzMDayalYRabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux diseaseAm J Gastroenterol2000953081811095321
- CarswellCIGoaKLRabeprazole: an update of its use in acid related disordersDrugs20016123275611772142
- CatalanoFTerminellaCBranciforteGEradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcerDigestion200266154912481161
- DamianoASiddiqueRXuXReductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazoleDig Dis Sci2003486576212741452
- De MilitoAFaisSProton pump inhibitors may reduce tumour resistanceExpert Opin Pharmacother2005610495415957961
- DeanBBSiddiqueRMYamashitaBDCost-effectiveness of proton pump inhibitors for maintenance therapy of erosive reflux esophagitisAm J Health Syst Pharm20015813384611471482
- DekkersCPBekerJAThjodleifssonBDouble-blind comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study GroupAliment Pharmacol Ther19991349579892879
- Di MarioFDal BoNAragonaGRabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosagesJ Gastroenterol Hepatol200318783612795749
- DickmanREmmonsSCuiHThe effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trialAliment Pharmacol Ther2005225475516167971
- DuboisDHughesDABodgerKEconomic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux diseasePharmacoeconomics20052310314116235976
- FarleyAWrubleLDHumphriesTJRabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study GroupAm J Gastroenterol2000951894910950032
- FassROfmanJJGastroesophageal reflux disease: should we adopt a new conceptual framework?Am J Gastroenterol2002971901912190152
- FeldmanMBurtonMEHistamine H2-receptor antagonistsN Engl J Med19903231672801978250
- FletcherJWirzAYoungJVallanceRMcCollKEUnbuffered highly acidic gastric juice exists at the gastroesophageal junction after a mealGastroenterology20011217758311606490
- FockKMTeoEKAngTLRabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban AsiaWorld J Gastroenterol2005113091815918196
- FuhrUJetterARabeprazole: pharmacokinetics and pharmacokinetic drug interactionsPharmazie20025759560112369444
- FurutaTShiraiNSugimotoMInfluence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapiesDrug Metab Pharmacokinet2005201536715988117
- GambaroCBilardiCDulbeccoPComparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a prelimary studyDig Liv Dis2003357637
- GardnerJDGallo-TorresHSloanSThe basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitisAliment Pharmacol Ther20031889190514616153
- GersonLBShetlerKTriadafilopoulosGControl of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett’s oesophagusDig Liv Dis2005376518
- GianniniEGBilardiCDulbeccoPA study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradicationAliment Pharmacol Ther200623281716393308
- GianniniEGMalfattiFBottaFInfluence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin and metronidazole on 13C-aminopyrine breath testDig Dis Sci20055012071316047461
- GibsonPGHenryRLCoughlanJLGastro-oesophageal reflux treatment for asthma in adults and childrenThe Cochrane Database of Systematic Reviews2003Issue 1 Art. No.: CD001496. DOI: 10.1002/14651858.CD001496
- GisbertJPKhorramiSCalvetXSystematic review: rabeprazole-based therapies in Helicobacter pylori eradicationAliment Pharmacol Ther2003177516412641497
- GisbertJPPajaresJMSystematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?Aliment Pharmacol Ther20052179580415801914
- HallJDoddSDurkinMAn impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costsManaged Care200211Suppl 714812181872
- HoltmannGBytzerPMetzMA randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux diseaseAliment Pharmacol Ther2002164798511876701
- HornJReview article: relationship between the metabolism and efficacy of proton pump inhibitors – focus on rabeprazoleAliment Pharmacol Ther200420Suppl 611915496214
- HuntRHArmstrongDJamesCEffect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteersAm J Gastroenterol200510019495616128938
- InamoriMTogawaJTakahashiKComparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?J Gastroenterol Hepatol2003181034812911659
- IshizakiTHoraiYReview article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazoleAliment Pharmacol Ther199913Suppl 3273610491726
- ItagakiFHommaMTakaraKEffect of rabeprazole on MDR1-mediated transport of Rhodamine 123 in Caco-2 and Hvr100-6 cellsBiol Pharm Bull2004271694615467223
- JaworskiTSarosiekISostarichSRestorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significanceDig Dis Sci2005503576515745101
- JiSKimHSKimJWComparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseasesJ Gastroenterol Hepatol20061716706799
- JohnssonFMoumBVilienMOn-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazoleScand J Gastroenterol200237pag6427
- JohansonJFSiddiqueRDamianoAMRabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux diseaseDig Dis Sci2002472574812452397
- JohnstonMHEastoneJAHorwhatJDCryoablation of Barrett’s esophagus: a pilot studyGastrointest Endosc200562842816301023
- KahrilasPJMinerPJohansonJEfficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux diseaseDig Dis Sci20055020091816240208
- KawabataHHabuYTomiokaHEffect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycinAliment Pharmacol Ther2003172596412534411
- KiviojaALinnosmaaIVehvilainenACost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusionsEur J Pharm Sci200421171814757488
- KlopockaMSinkiewiczABudzynskiJImprovement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazoleMed Sci Monit200410PI115815448612
- KromerWKrugerUHuberRDifferences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlatesPharmacology19985657709494064
- LewEABarbutiRCKovacsTOAn ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810)Aliment Pharmacol Ther199812667729701531
- LuoJYNiuCYWangXQEffect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitudeWorld J Gastroenterol20039112583614606102
- Mat SaadAZCollinsNLoboMMProton pump inhibitors: a survey of prescribing in an Irish general hospitalInt J Clin Pract20055931415707461
- McCollKELKennerleyPProton pump inhibitors – differences emerge in hepatic metabolismDig Liv Dis2002344617
- McGowanBBennettKTilsonLCost-effective prescribing of proton pump inhibitors (PPI’s) in the GMS SchemeIr Med J200598788015869064
- MinerPJrOrrWFilipponeJRabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trialAm J Gastroenterol2002971332912094846
- OdaKIwakiriRHaraMDysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitorDig Dis Sci2005501921616187198
- OfmanJJDornGHFennertyMBThe clinical and economic impact of competing management strategies for gastro-oesophageal reflux diseaseAliment Pharmacol Ther2002162617311860409
- OfmanJJYamashitaBDSiddiqueRMCost-effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitisAm J Manag Care200069051611186502
- OhningGVWalshJHPisegnaJRRabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjectsAliment Pharmacol Ther20031711091412752347
- OribeYFujimuraMKitaTAttenuating effect of H+K+ATPase inhibitors on airway cough hypersensitivity induced by allergic airway inflammation in guinea-pigsClin Exp Allergy200535262715784101
- OrrWCGoodrichSRobertJThe effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal refluxAliment Pharmacol Ther200521103815679759
- PaceFAnneseVPradaARabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomized, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux, followed by a maintenance open-label, low-dose therapy with rabeprazoleDig Liver Dis2005377415016024305
- PaceFBianchi-PorroGGastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed)Am J Gastroenterol200499946915128365
- PaceFPallottaSBianchi PorroGOn demand proton pump therapy in patients with gastro-esophageal reflux diseaseDig Liver Dis200234870712643297
- PantoflickovaDDortaGRavicMAcid inhibition on the first day of dosing: comparison of four proton pump inhibitorsAliment Pharmacol Ther20031715071412823153
- PehlivanovNDOlyaeeMSarosiekIComparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over studyAliment Pharmacol Ther2003188839014616152
- PonceJArguelloLBastidaGOn-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfactionDig Dis Sci200449931615309880
- RemakEBrownREYuenCCost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UKCurr Med Res Opin20052115051716238890
- RielMAKyleDEBhattacharjeeAKEfficacy of proton pump inhibitor drugs against Plasmodium falciparum in vitro and their probable pharmacophoresAntimicrob Agents Chemother20024626273212121943
- RobinsonMFitzgeraldSHegedusROnset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitisAliment Pharmacol Ther2002164455411876697
- SaitohTFukushimaYOtsukaHEffects or rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizersAliment Pharmacol Ther2002161811712269976
- SakaiTAoyamaNKitaTCYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjectsPharm Res200118721711474773
- SarelaAIHickDGVerbekeCSPersistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapyArch Surg20041395475115136356
- ShimataniTInoueMKuroiwaTAcid-suppressive effects of rabeprazole, omeprazole and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19Clin Pharmacol Ther2006791445216413249
- ShiraiNFurutaTMoriyamaYEffects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pHAliment Pharmacol Ther20011519293711736724
- SkoczylasTSarosiekISostarichSSignificant enhancement of gastric mucin content after rabeprazole administration. Its potential clinical significance in acid-related disordersDig Dis Sci200348322812643610
- SloanSRabeprazole-based therapy in the management of symptomatic gastroesophageal reflux diseaseAm J Gastroenterol2003983 SupplS49S5512644031
- StewardDLWilsonKMKellyDHProton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trialOtolaryngol Head Neck Surg20041313425015467597
- SwanSKHoyumpaAMMerrittGJReview article: the pharmacokinetics of rabeprazole in health and diseaseAliment Pharmacol Ther199913Suppl 311710491724
- SwiatkowskiMBudzynskiJKlopockaMSuppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery diseaseMed Sci Monit200410CR524915328486
- ThjodleifssonBCockburnIReview article: rabeprazole’s tolerability profile in clinical trialsAliment Pharmacol Ther199913Suppl 5172310555605
- ThjodleifssonBRindiGFioccaRA randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 yearsAliment Pharmacol Ther2003173435112562446
- ThjodleifssonBReview of rabeprazole in the treatment of gastro-oesophageal reflux diseaseExpert Opin Pharmacother200451374914680443
- ThjodleifssonBBekerJADekkersCRabeprazole vs omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double blind multicenter European trial. The European Rabeprazole Study GroupDig Dis Sci2000458455310795744
- TolmanKGTäubelJWarringtonSComparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteersClin Drug Invest200626218
- TsugenoHMizunoMFujikiSA proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal refluxScand J Gastroenterol2003384566112795453
- VakilNLanzaFSchwartzHSeven-day therapy for Helicobacter pylori in the United StatesAliment Pharmacol Ther2004209910715225176
- Van HerwaardenMASamsonMSmoutAJHelicobacter pylori eradication increases nocturnal acid breakthroughAliment Pharmacol Ther200014961210886054
- VoLSimonianHPDomaSThe effect of rabeprazole on regional gastric acidity and the postprandial cardia/gastro-oesophageal junction acid layer in normal subjects: a randomized, double-blind, placebo-controlled studyAliment Pharmacol Ther20052113213015932362
- WangHChouJLiaoKOne-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapyWorld J Gastroenterol2005111680415786549
- WaniSSamplinerREWestonAPLack of predictors of normalization of oesophageal acid exposure in Barrett’s oesophagusAliment Pharmacol Ther2005226273316181302
- WarringtonSBaisleyKBoyceMEffects of rabeprazole 20 mg, or esomeprazole 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjectsAliment Pharmacol Ther2002161301712144580
- WilliamsMPSercombeJHamiltonMIA placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjectsAliment Pharmacol Ther1998121079899845397
- WitNJBoerWAGeldofHTreatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?Aliment Pharmacol Ther200420451815298640
- WongBCYWongWMYeeYKRabeprazole-based 3-day and 7-day triple therapy vs omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infectionAliment Pharmacol Ther20011519596511736727
- YangKWangGChenJComparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcerJ Formos Med Assoc20031028576214976565